See clinical tips available (linked below) on individual LAIs for more detailed information about what clinicians should know.
LAI Drug Name | FDA Indications | Dosing Tips |
***First Generation Antipsychotics*** | ||
Schizophrenia | 4 weeks | |
Schizophrenia | 2 weeks | |
***Second Generation Antipsychotics*** | ||
Schizophrenia | 4 weeks One Day Initiation or Overlap PO 2 weeks | |
Schizophrenia | 4 or 6 or 8 weeks | |
Initiation of Maintenance Aristada (aripiprazole lauroxil LAI) in Schizophrenia | Only for initiation of Aristada once | |
Erzofri (paliperidone palmitate LAI) | Schizophrenia Schizoaffective Disorder | 4 weeks |
Schizophrenia | 4 weeks | |
Schizophrenia | 6 months; after adequately treated with paliperidone palmitate once monthly for at least 4 months OR INVEGA TRINZA for at least one three-month cycle | |
Schizophrenia | 12 weeks; after adequately treated with paliperidone palmitate once monthly for at least four months, with the last 2 doses of INVEGA SUSTENNA at the same dosage strength | |
Schizophrenia | 2 weeks | |
Schizophrenia | 4 or 8 weeks | |